Research Partnership continues to expand in the US
We are pleased to announce a number of appointments across our US offices.
Mariana Servin has joined the company’s New York office as Quantitative Director. Mariana has over 18 years’ experience in market research and consulting for pharmaceutical, biotech, medical device and life science clients. She has worked in senior roles for a variety of research and advisory organisations including Quintiles Consulting, Decisions Resources Group and Ipsos Healthcare. Mariana has a wealth of experience in both qualitative and quantitative research, including global work covering Europe, Asia-Pacific and Latin American markets. She joins Research Partnership with a remit for supporting the quantitative side of the business, especially in advanced analytics.
Game changer? The role of virtual reality in healthcare
In the first installment of three-part series exploring virtual and augmented reality, Harrison Gaiger outlines the medical applications of VR and how pharma can leverage this innovative technology in the future.
The next decade promises to be an exciting time for science and innovation. Technological advancements are being made on a daily basis and many of these have the potential to directly impact our everyday lives. In fact, technology is changing at such a rate that it can often seem difficult to keep up. One technological advancement with the potential to change how we interact with technology and each other is Virtual Reality (VR) – immersive computer-generated environments that place users in seemingly life-like situations with which they can interact. VR, once the stuff of science-fiction, is now becoming a viable mainstream product.
Infographic - Emerging markets: Our experience and expertise
Find out about our team of emerging market experts with this infographic outlining our experience and expertise across a vast number of regions, with links to a number of free resources.
JAK inhibitors gaining traction for rheumatoid arthritis in EU5
The new class of JAK inhibitor therapies is making a strong impression in the European market for rheumatoid arthritis (RA), according to recent prescribing data from specialist physicians.
Our latest Therapy Watch RA study, conducted in the key EU5 countries (France, Germany, Italy, Spain and the UK), found that in the dynamic segment of the RA market – defined as patients who have started or switched onto their current RA treatment in the three months preceding inclusion in the study – the orally -administered JAK inhibitors expanded their market share across the EU5 from 3.1% in the third quarter of 2017 to 15.6% in the second quarter of 2018.
Best practice for conducting UX research
US Director, Liza Pliss explains why User Experience and Usability testing is essential for optimising the value of digital assets such as websites, apps, and other digital tools.